Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
Develops gene therapies for cardiovascular and CNS diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Gene therapy trial aims to repair hearts in rare neurological disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2006 in 8 people with Friedreich's ataxia who also have heart muscle disease. The therapy delivers a healthy copy of the FXN gene to heart cells using a modified virus. The main goal is to check safety over 5 years, while also …
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Gene therapy for rare heart disease passes early safety check
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understan…
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC